Equities

Acticor Biotech SA

Acticor Biotech SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.852
  • Today's Change-0.04 / -4.48%
  • Shares traded28.96k
  • 1 Year change-85.26%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 14:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acticor Biotech SAS is a France-based company. The Company is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-18.65m
  • Incorporated2013
  • Employees24.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Theranexus SA0.00-6.83m8.38m19.00--3.77-----1.09-1.090.000.28630.00----0.00-70.79-42.66-82.29-47.97-----------1,058.680.6212-------3.97---33.23--
Quantum Genomics SA10.06k-3.17m9.05m3.00--10.36--899.44-0.091-0.0910.00030.01250.0007--0.00163,353.33-23.14-60.77-95.19-102.24-14,205.07-3,548.91-31,520.38-3,374.13---146.530.8615---98.34--87.28------
Acticor Biotech SA0.00-18.65m14.05m24.00--29.91-----1.68-1.680.000.02980.00----0.00-145.59---297.22-------------9.320.9504-------25.94------
Plant Advanced Technologies PAT SA2.34m-849.00k15.10m56.00--2.05--6.46-0.7853-0.78532.156.700.13680.98692.8741,767.86-4.91-3.18-7.20-4.0422.8398.91-35.87-27.900.8691-16.730.4472--1.4823.7225.13--3.57--
Ikonisys SA538.56k-2.40m15.36m11.00--0.8406--28.53-0.2499-0.24990.0561.750.02461.146.2048,960.00-10.94---12.55--2.72---444.76--0.0818-36.790.1007--68.94---328.57------
Valerio Therapeutics SA1.80m-20.34m16.58m19.00--1.12--9.21-0.1566-0.15660.01330.09610.0459--1.0794,736.84-51.92-34.19-67.72-40.5970.3984.11-1,130.22-586.99---171.660.3776--24.74-21.73-4.00--32.39--
SMAIO SA7.62m1.06m18.30m37.0017.181.697.692.400.20380.20381.462.070.56240.187117.23206,027.607.81-7.8710.24-19.7696.9596.0413.89-22.482.5411.070.1991--212.18114.99-62.80------
NicOx SA3.57m-17.36m18.51m11.00--0.4032--5.18-0.3721-0.37210.07530.91280.0394--1.83324,909.10-19.13-19.22-21.35-20.78-----485.70-370.14----0.3172---54.787.2536.57---13.35--
Phaxiam Therapeutics SA1.33m-23.49m18.65m51.00--0.7282--14.07-5.56-5.560.31394.220.0273--14.8226,000.00-48.37-50.69-66.94-66.25-----1,771.42-1,009.09---70.210.3412---80.05-21.50-10,201.75---56.68--
Nfl Biosciences SAS0.00-3.48m20.96m3.00--5.32-----0.5396-0.53960.000.40970.00----0.00-80.79---125.59--------------0.0228-------149.78------
Data as of May 23 2024. Currency figures normalised to Acticor Biotech SA's reporting currency: Euro EUR

Institutional shareholders

0.18%Per cent of shares held by top holders
HolderShares% Held
Friedland Gestion SASas of 31 Jan 202424.80k0.16%
Olympia Wealth Management Ltd.as of 30 Jun 20233.00k0.02%
Data from 31 Jan 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.